Computational Modeling of Viral Envelope Protein Dynamics: Implications for Vaccine Design

Introduction

Viral envelope glycoproteins mediate critical steps in the viral life cycle, including host receptor recognition, membrane fusion, and entry into target cells [1, 2]. These proteins are primary targets for host neutralizing antibodies and consequently undergo intense selective pressure that drives antigenic drift [3, 4]. Understanding the structural and dynamic properties of envelope proteins is therefore essential for rational vaccine design. Computational modeling provides a powerful platform to predict conformational changes, assess receptor binding affinities, and forecast immune evasion mutations at atomic resolution [5, 6, 7]. This review examines the principal computational techniques applied to veterinary viral envelope proteins and discusses their implications for vaccine development.

Homology Modeling and Structure Prediction

Homology modeling remains a foundational technique for building three-dimensional structures of envelope proteins when experimental data are limited. The approach relies on sequence alignment to a known template structure, followed by loop refinement and side-chain optimization [2, 8]. Class I fusion proteins, such as influenza hemagglutinin (HA) and paramyxovirus fusion (F) proteins, share a characteristic prefusion conformation that can be modeled using tools like AlphaFold2 [2]. The accuracy of these models is critical for downstream docking and dynamics studies.

Recent work has demonstrated the utility of AlphaFold2 in predicting both pre- and postfusion conformations of class I fusion proteins, enabling the identification of metastable intermediates that are vulnerable to antibody neutralization [2]. For veterinary pathogens, homology models of envelope proteins from porcine epidemic diarrhea virus (PEDV) and Newcastle disease virus (NDV) have been constructed to map mutational landscapes and receptor binding interfaces [9, 10]. In silico characterization of the SARS-CoV-2 envelope protein has also been performed using homology modeling to identify inhibitor binding sites [11]. The quality of these models is assessed through Ramachandran plots, QMEAN scores, and MolProbity statistics, which are essential for ensuring reliable downstream simulations [8].

Molecular Dynamics Simulations of Conformational Transitions

Molecular dynamics (MD) simulations provide atomistic detail on the timescales of conformational rearrangements that occur during receptor binding and membrane fusion [12, 13, 7]. All-atom MD simulations of viral envelope proteins typically employ force fields such as AMBER or CHARMM, with explicit solvent and lipid bilayers to mimic the native membrane environment [14, 15]. The simulations capture critical transitions, including the opening of the receptor-binding domain (RBD) in coronaviruses and the spring-loaded conformational change in influenza HA [7, 4].

For SARS-CoV-2 spike protein, MD studies have revealed how the D614G mutation reshapes allosteric networks and opening mechanisms, increasing the propensity for RBD exposure and enhancing ACE2 binding [7]. Similar analyses have been applied to the hemagglutinin-neuraminidase (HN) proteins of paramyxoviruses and the G protein of rabies virus, revealing pH-dependent conformational shifts that prime the fusion machinery [9, 16]. Ligand-induced modulations have also been explored, such as the interaction of HSPA8 with the SARS-CoV-2 spike protein, which was characterized using in-depth MD simulations that identified key binding hotspots [13].

Free Energy Landscapes and Binding Affinity

Quantifying the energetics of envelope protein interactions with host receptors is essential for predicting host range and immune pressure [17, 18, 19]. Free energy perturbation (FEP) and molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) methods are routinely employed to calculate binding free energies between viral glycoproteins and receptor molecules or antibodies [20, 18, 21]. These calculations can predict the impact of point mutations on binding affinity and inform the selection of vaccine antigens.

For example, computational alanine scanning combined with MM/PBSA has been used to map the receptor-binding region of the dengue virus E protein and to evaluate the effect of N-glycosylation on HIV-1 Env trimer tilting [1, 22]. In the context of equine influenza, free energy landscapes derived from umbrella sampling simulations have elucidated the sialic acid binding preferences of HA, which correlate with host tropism. The identification of strain-specific O-glycosylation sites in Zika virus E protein similarly relied on energy-based analyses that revealed potential immune shielding mechanisms [23].

Machine Learning and Mutational Analysis

The rapid emergence of viral variants necessitates computational methods that can keep pace with antigenic drift [5, 3, 4]. Machine learning models trained on large datasets of sequence and structural features can predict the impact of mutations on antibody escape, receptor binding, and protein stability [5, 6, 24]. Combining iterative experimental screening with machine learning has proven effective for monitoring variants of concern and updating vaccine compositions in real time [5].

Deep mutational scanning data are now integrated with structural modeling to construct fitness landscapes for envelope proteins [25, 4]. For influenza A virus, the convergent evolution of the N156K mutation in hemagglutinin was identified through such approaches as a key driver of antigenic drift and cluster transition [3]. In the case of SARS-CoV-2, hierarchical mutational profiling combined with energy landscape analysis has been used to rank broadly neutralizing antibody resistance mechanisms [6]. Similar workflows are being adapted for veterinary pathogens such as canine influenza virus and PEDV, where glycosylation site shifts and epitope remodeling are monitored using computational pipelines that link sequence surveillance to structural prediction [25, 10].

Implications for Vaccine Design

Rational vaccine design leverages computational insights to select immunogens that elicit broadly neutralizing antibodies [26, 21, 27]. By modeling the prefusion conformation of envelope proteins, researchers can stabilize key epitopes through structure-guided engineering, as demonstrated for respiratory syncytial virus (RSV) F protein and coronavirus spike proteins [28, 16]. Immunoinformatic tools further refine this process by predicting B-cell and T-cell epitopes, enabling the construction of multi-epitope vaccines targeting conserved regions of the envelope protein [26, 27].

For veterinary applications, computational modeling has been used to design peptide-based inhibitors and subunit vaccines against white spot syndrome virus in shrimp, African swine fever virus in swine, and avian influenza virus in poultry [8, 21, 29]. The integration of MD simulations with virtual screening allows the identification of small-molecule inhibitors that block envelope protein function, as shown for the IAV M2 channel [29] and the SARS-CoV-2 envelope protein [11]. These approaches accelerate the development of both prophylactic vaccines and therapeutic antivirals.

Workflow for Computational Envelope Protein Analysis

The following diagram summarizes a typical computational pipeline for studying viral envelope protein dynamics in the context of vaccine design:

flowchart TD
    A[Sequence Input], > B[Homology Modeling / AlphaFold2]
    B, > C[Structure Validation & Refinement]
    C, > D[Molecular Dynamics Simulations]
    D, > E[Conformational Analysis & Free Energy Calculation]
    E, > F[Machine Learning Mutational Screening]
    F, > G[Epitope Prediction & Immunoinformatics]
    G, > H[Vaccine Antigen Design]
    H, > I[In vitro / In vivo Validation]
    I, > J[Surveillance & Update Cycle]
    J, > A

This iterative cycle highlights the importance of continuous feedback between computational predictions and experimental testing, particularly as viral variants emerge [5, 3].

Conclusion

Computational modeling of viral envelope protein dynamics has become indispensable for modern vaccinology. Homology modeling, molecular dynamics simulations, free energy calculations, and machine learning collectively provide a detailed understanding of how envelope proteins function, evolve, and evade immune responses. These methods enable the rational design of stabilized immunogens and the real-time surveillance of antigenic drift in veterinary pathogens. Continued advances in computational power and algorithmic accuracy will further refine our ability to predict viral emergence and to develop broadly protective vaccines for animal populations.

References

[1] Cao Y, Im W. Conformational variability of HIV-1 Env trimer and viral vulnerability. Elife. 2026. doi:10.7554/eLife.42360802. URL: https://pubmed.ncbi.nlm.nih.gov/42360802/

[2] Gülesen S, Most V, Schoeder CT, et al. Prediction of pre- and postfusion conformations of class I fusion proteins with AlphaFold2. PLoS One. 2026. doi:10.1371/journal.pone.42302011. URL: https://pubmed.ncbi.nlm.nih.gov/42302011/

[3] Tian Y, Jiang D, Ma W, et al. Convergent evolution of the N156K mutation in A(H1N1)pdm09 hemagglutinin contributes to antigenic drift and cluster transition. Emerg Microbes Infect. 2026. doi:10.1080/22221751.2026.42267384. URL: https://pubmed.ncbi.nlm.nih.gov/42267384/

[4] Soliman OA, Shahine Y, Baecker D, et al. Beyond the Mutation Abyss: Revisiting SARS-CoV-2 Receptor-Binding Domain Evolution from ACE2 Binding Optimization to Immune Epitope Remodeling. Pathogens. 2026. doi:10.3390/pathogens41901725. URL: https://pubmed.ncbi.nlm.nih.gov/41901725/

[5] Sheffield T, Bruneau RC, Won S, et al. Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern. PLoS Comput Biol. 2026. doi:10.1371/journal.pcbi.42308256. URL: https://pubmed.ncbi.nlm.nih.gov/42308256/

[6] Alshahrani M, Gatlin W, Ludwick M, et al. Mechanisms of Binding and Immune Escape Resistance for Broadly Neutralizing Antibodies Targeting Distinct Conserved SARS-CoV-2 Spike Epitopes: A Hierarchical Approach Integrating Mutational Profiling and Energy Landscape Analysis. Int J Mol Sci. 2026. doi:10.3390/ijms42123600. URL: https://pubmed.ncbi.nlm.nih.gov/42123600/

[7] Kearns FL, Bogetti AT, Calvó-Tusell C, et al. D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes. Proc Natl Acad Sci U S A. 2026. doi:10.1073/pnas.42101997. URL: https://pubmed.ncbi.nlm.nih.gov/42101997/

[8] Hossen Z, Sajjad Hossain M, Naim Uddin Forhad M, et al. Multi-target inhibitors of white spot syndrome virus envelope proteins (VP28, VP26, and VP24) to protect shrimp (Penaeus monodon): An integrated virtual screening, pharmacokinetic, and molecular dynamics study. Microb Pathog. 2026. doi:10.1016/j.micpath.2026.42055173. URL: https://pubmed.ncbi.nlm.nih.gov/42055173/

[9] Lu K, Tong L, Daguia-Wenam P-T, et al. Genotype IX Newcastle disease virus isolated from wild birds is attenuated by hemagglutinin-neuraminidase mutation. J Virol. 2026. doi:10.1128/jvi.42159397. URL: https://pubmed.ncbi.nlm.nih.gov/42159397/

[10] Gao M, Liu Y, Xu X, et al. Temporal evolutionary dynamics of porcine epidemic diarrhea virus in China from 2013 to 2023. Infect Genet Evol. 2026. doi:10.1016/j.meegid.2026.41962875. URL: https://pubmed.ncbi.nlm.nih.gov/41962875/

[11] Kobe N, Dreisewerd L, Lukšič M, et al. In silico characterisation of a novel SARS-CoV-2 envelope protein inhibitor and in vitro validation against murine coronavirus. Bioorg Chem. 2026. doi:10.1016/j.bioorg.2026.42119203. URL: https://pubmed.ncbi.nlm.nih.gov/42119203/

[12] Urano R, Yoshimoto S, Hori K, et al. Synergistic Protein-Protein and Protein-Lipid Interactions Drive SARS-CoV-2 Envelope Assembly. J Chem Inf Model. 2026. doi:10.1021/acs.jcim.42262910. URL: https://pubmed.ncbi.nlm.nih.gov/42262910/

[13] Navhaya LT, Monama MZ, Matsebatlela TM, et al. In-Depth Molecular Dynamics Simulations Reveal Ligand-Induced Modulations of the HSPA8-SARS-CoV-2 Spike Protein Interaction. Int J Mol Sci. 2026. doi:10.3390/ijms42196270. URL: https://pubmed.ncbi.nlm.nih.gov/42196270/

[14] McTiernan J, Zhang Y, Li S, et al. Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes. PLoS Comput Biol. 2026. doi:10.1371/journal.pcbi.42044155. URL: https://pubmed.ncbi.nlm.nih.gov/42044155/

[15] Ataya F, Alamro A, Alghamdi A, et al. Identification of polyphenols as novel neuropilin-1 cendR pocket inhibitors to block SARS-CoV-2 entry and enhance variant resistance. PLoS One. 2026. doi:10.1371/journal.pone.41871083. URL: https://pubmed.ncbi.nlm.nih.gov/41871083/

[16] Dubey A, Kumar M, Tufail A. Suppressing viral assembly in human metapneumovirus by targeting fusion protein with natural compounds: a structural dynamics and energetics study. J Mol Model. 2026. doi:10.1007/s00894-026-42043606. URL: https://pubmed.ncbi.nlm.nih.gov/42043606/

[17] Delgado-Maldonado T, Vargas-Salas G, Bandyopadhyay D, et al. Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction. ChemMedChem. 2026. doi:10.1002/cmdc.202600743. URL: https://pubmed.ncbi.nlm.nih.gov/42174382/

[18] Kongtaworn N, Sinsulpsiri S, Hanpaibool C, et al. Molecular Dynamics and Solvated Interaction Energy Prioritize Cannabidiol and Cannabinol as Variant-Spanning SARS-CoV-2 RBD-ACE2 Interface Blockers. Molecules. 2026. doi:10.3390/molecules42075932. URL: https://pubmed.ncbi.nlm.nih.gov/42075932/

[19] Cofas-Vargas LF, Olivos-Ramirez GE, Marrink SJ, et al. A comparative nanomechanical study of antibody and nanobody binding to SARS-CoV-2 variants. Phys Chem Chem Phys. 2026. doi:10.1039/D6CP41885290. URL: https://pubmed.ncbi.nlm.nih.gov/41885290/

[20] Kumar A, Yadav AJ, Tripathi T, et al. Glycan shielding and epitope reorganization drive sotrovimab resistance in SARS-CoV-2 Omicron variants. Arch Biochem Biophys. 2026. doi:10.1016/j.abb.2026.42128042. URL: https://pubmed.ncbi.nlm.nih.gov/42128042/

[21] Ait Lahcen N, Liman W, Zekri S, et al. QSAR-Guided and Fragment-Based Drug Design of Monoterpenoid Inhibitors Targeting Ebola Virus Glycoprotein. Int J Mol Sci. 2026. doi:10.3390/ijms41977174. URL: https://pubmed.ncbi.nlm.nih.gov/41977174/

[22] Shehata M, Casalino L, Duquette M, et al. N-Glycans modulate tilting of HIV-1 envelope glycoprotein. Nat Commun. 2026. doi:10.1038/s41467-026-41986331. URL: https://pubmed.ncbi.nlm.nih.gov/41986331/

[23] Kori L, Chandra A, Mukhopadhyay L, et al. E-protein variability in Zika virus strains: A possible new O-glycosylation site and its implications. Indian J Med Res. 2026. doi:10.4103/ijmr.ijmr_42165713. URL: https://pubmed.ncbi.nlm.nih.gov/42165713/

[24] Pravin MA, Khan MA, Singh SK. Identification of potent inhibitors targeting the pre-fusion DENV envelope protein: A consensus physics-and AI-based in silico multi-tier screening approach. Biochem Biophys Res Commun. 2026. doi:10.1016/j.bbrc.2026.42008872. URL: https://pubmed.ncbi.nlm.nih.gov/42008872/

[25] Altaf M, Kin Cheng MT, González-Vázquez LD, et al. SARS-CoV-2 intra-host recombination promotes epistatic spike interactions and temperature-dependent adaptation. Cell Rep. 2026. doi:10.1016/j.celrep.2026.42213788. URL: https://pubmed.ncbi.nlm.nih.gov/42213788/

[26] Sugumar M, Pragalath S, Kugarajah V. Immunoinformatics-based epitope prediction in MERS-CoV and docking analysis of Catharanthus roseus compounds for drug discovery. Comput Biol Chem. 2026. doi:10.1016/j.compbiolchem.2026.42218862. URL: https://pubmed.ncbi.nlm.nih.gov/42218862/

[27] Naveed M, Ali A, Aziz T, et al. Identification of a novel multi epitope vaccine against human herpes virus 7 (HHV-7) to combat CNS disorders in children and adolescents using subtractive proteomics and immunoinformatic approaches. Hum Immunol. 2026. doi:10.1016/j.humimm.2026.41905024. URL: https://pubmed.ncbi.nlm.nih.gov/41905024/

[28] Zhou X, Du H, Wang C, et al. Identification of a Potential Dual-Target Candidate Against RSV F Protein and 15-LOX from TCMSP: Integrating Virtual Screening, Molecular Dynamics, and Experimental Evaluation. Int J Mol Sci. 2026. doi:10.3390/ijms42074092. URL: https://pubmed.ncbi.nlm.nih.gov/42074092/

[29] Chen M, Chen W, Jiang X, et al. Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline. Biochem Biophys Res Commun. 2026. doi:10.1016/j.bbrc.2026.41881854. URL: https://pubmed.ncbi.nlm.nih.gov/41881854/

[30] Gayakvad B, Alagarasu K, Patel R, et al. Antiviral Potential of Onosma bracteata Against Chikungunya Virus: Experimental Validation and Computational Mechanistic Study. Appl Biochem Biotechnol. 2026. doi:10.1007/s12010-026-42287533. URL: https://pubmed.ncbi.nlm.nih.gov/42287533/

[31] Timofeeva AM, Aulova KS, Ulyanova YS, et al. Molecular Mimicry by the Tick-Borne Encephalitis Virus E Protein: A Hidden Link to Autoimmunity. Int J Mol Sci. 2026. doi:10.3390/ijms42278275. URL: https://pubmed.ncbi.nlm.nih.gov/42278275/

[32] Smatti MK, Al-Khatib H, Suleman M, et al. Functional and structural characterization of the SARS-CoV-2 spike N481K mutation. Arch Virol. 2026. doi:10.1007/s00705-026-42243594. URL: https://pubmed.ncbi.nlm.nih.gov/42243594/

[33] Alotaiq N, Dermawan D, Chtita S. Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain. Microbiologyopen. 2026. doi:10.1002/mbo3.70042. URL: https://pubmed.ncbi.nlm.nih.gov/42082899/

[34] Salam DDA. In silico screening and molecular dynamics simulations of Epicatechin as an inhibitor of EBV LMP1. J Mol Graph Model. 2026. doi:10.1016/j.jmgm.2026.41955735. URL: https://pubmed.ncbi.nlm.nih.gov/41955735/

[35] Silva-Díaz A, Thépaut M, Ramírez-Cárdenas J, et al. Enhancing lectin recognition via precise fluorination: Man(5) glycomimetics for targeting DC-SIGN. Bioorg Chem. 2026. doi:10.1016/j.bioorg.2026.41856064. URL: https://pubmed.ncbi.nlm.nih.gov/41856064/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.